Outperformance of the pharmaceutical sector during the COVID-19 pandemic: Global time-varying screening rule development

Esparcia, Carlos; Garcí­a, Raquel López

doi:10.1016/j.ins.2022.07.146

Cited by 7 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COVID-19 pandemic gives us many lessons. Several sectors experienced a decline in their business, but the pharmaceutical industry still survive and has grown significantly (Esparcia and López, 2022;Lim and Rokhim, 2021). Furthermore, Indonesian pharmaceutical sector has experienced rapid growth since the implementation of the Indonesian National Health Insurance (JKN) program in 2014 (Theodore et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

Hermawan,

Hadiyati,

Adiarso

et al. 2023

JAKI

View full text Add to dashboard Cite

Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&D, high costs of development and time consuming, and low innovation incentives. Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022. Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&D. Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera. Keywords: pharmaceutical raw materials, policy, pharmaceutical

show abstract

Section: Introductionmentioning

confidence: 99%

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

Hermawan,

Hadiyati,

Adiarso

et al. 2023

JAKI

View full text Add to dashboard Cite

show abstract

European Healthcare and Biotechnology-Related Mutual Funds and Sustainable Development During COVID-19

Martí-Ballester

2023

SDGs in the European Region

View full text Add to dashboard Cite

European Healthcare and Biotechnology-Related Mutual Funds and Sustainable Development During COVID-19

Martí-Ballester

2023

Implementing the UN Sustainable Development Goals – Regional Perspectives

View full text Add to dashboard Cite

Outperformance of the pharmaceutical sector during the COVID-19 pandemic: Global time-varying screening rule development

Cited by 7 publications

References 41 publications

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

Challenges and Policy Supports in Indonesian Pharmaceutical Raw Materials Industry

European Healthcare and Biotechnology-Related Mutual Funds and Sustainable Development During COVID-19

European Healthcare and Biotechnology-Related Mutual Funds and Sustainable Development During COVID-19

Contact Info

Product

Resources

About